A remyelinating agent remains a distant hope
But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
The heat is on for Oxford Nanopore
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
The lung fibrosis pipeline thins
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Biogen leads the amyotrophic lateral sclerosis hopefuls
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
No let-up in Covid-19 vaccine trials
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Tecentriq pullout dominates the latest PD-(L)1 moves
July and August saw key regulatory and clinical developments for several anti-PD-(L)1 MAbs, with plenty more in store for oncology watchers.
Cytokine interest shows no sign of waning
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
Why some Spac deals are not all they’re cracked up to be
While blank-cheque mergers can net healthtechs a huge amount of capital, not all investors stay the course.
